Diabetes and thromboembolic risk

CPD QUESTIONNAIRE

EARN FREE CPD POINTS

Complete, scan and email to **cpd@denovomedica.com**. Alternatively, you can complete this questionnaire online at **www.denovomedica.com**. Fill in your details using **clear block letters** and mark the answers with a tick (✓).

I agree that my CPD-accredited certificate will be forwarded to my e-mail address. (Online) _____

(Signature of healthcare professional)

First Name		**Profession**	
Surname		**Telephone**	
HPC No.		**City**	
E-mail			

1. Of diabetic patients, approximately __% have albuminuria?

☐ **A** 10% ☐ **B** 20% ☐ **C** 28%

2. Of diabetic patients, approximately __% have both albuminuria and impaired renal function?

☐ **A** 10% ☐ **B** 20% ☐ **C** 28%

3. Which statement is true?

☐ **A** Diabetes and hypertension are the most common causes of CKD
☐ **B** Albuminuria and/or impaired renal function significantly increase mortality risk in the diabetic patient
☐ **C** A and B

4. Which statement is false?

☐ **A** Diabetes has been identified as a strong independent risk factor for AF in a large American Veterans registry
☐ **B** Framingham study data reflect a 60% increased risk of AF in the diabetic patient
☐ **C** T2DM with AF is associated with increased all-cause mortality and major cardiovascular events over five years

5. In the ADVANCE trial, the RRI for all deaths in T2DM was ___% in the presence of AF, compared to no AF?

☐ **A** 46% ☐ **B** 54% ☐ **C** 61%

6. In the ADVANCE trial, the RRI for major cerebrovascular events in T2DM patients was ___% in the presence of AF, compared to no AF?

☐ **A** 61% ☐ **B** 68% ☐ **C** 71%

7. Risk for development of AF is further increased in the patient with:

☐ **A** CKD ☐ **B** The metabolic syndrome ☐ **C** A and B

8. The RELOADED study of diabetic patients with NVAF:

☐ **A** Compared apixaban against phenprocoumon
☐ **B** Compared rivaroxaban against phenprocoumon
☐ **C** Showed reduced risk for end-stage renal disease and slowed progression to AKI
☐ **D** All of the above
☐ **E** B and C only

9. Real-world data from diabetes patients with AF show equivalent renal protection using rivaroxaban treatment compared to warfarin.

☐ **A** True ☐ **B** False

10. In the ROCKET AF trial comparing rivaroxaban against warfarin, approximately ___% of patients had T2DM?

☐ **A** 20% ☐ **B** 40% ☐ **C** 60%

11. Real-world data reflect consistency with the results of ROCKET AF showing benefit of rivaroxaban over warfarin for stroke/systemic embolism, major bleeding and intracranial haemorrhage in the diabetic patient with NVAF.

☐ **A** True ☐ **B** False

12. Compared to warfarin, rivaroxaban use in patients with T2DM and NVAF has been associated with lower risk of:

☐ **A** MACE ☐ **B** MALE ☐ **C** A and B

Case study

13. Should the patient be anticoagulated?

☐ **A** Yes ☐ **B** No

14. When deciding to anticoagulate, what should be the choice of anticoagulant?

☐ **A** Vitamin K antagonist - warfarin ☐ **B** Aspirin ☐ **C** NOAC

15. Is there a treatment that could offer benefits beyond stroke prevention in this patient's case?

☐ **A** Yes ☐ **B** No

© 2020 deNovo Medica